JP6283661B2 - 一塩基KRAS変異に特異的な二機能性低分子ヘアピン型RNA(BI−SHRNA,Bi−functionalShort−HairpinRNA) - Google Patents
一塩基KRAS変異に特異的な二機能性低分子ヘアピン型RNA(BI−SHRNA,Bi−functionalShort−HairpinRNA) Download PDFInfo
- Publication number
- JP6283661B2 JP6283661B2 JP2015511715A JP2015511715A JP6283661B2 JP 6283661 B2 JP6283661 B2 JP 6283661B2 JP 2015511715 A JP2015511715 A JP 2015511715A JP 2015511715 A JP2015511715 A JP 2015511715A JP 6283661 B2 JP6283661 B2 JP 6283661B2
- Authority
- JP
- Japan
- Prior art keywords
- shrna
- mutant
- bifunctional
- expression
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091027967 Small hairpin RNA Proteins 0.000 title claims description 170
- 239000004055 small Interfering RNA Substances 0.000 title claims description 159
- 230000001588 bifunctional effect Effects 0.000 title claims description 119
- 206010069755 K-ras gene mutation Diseases 0.000 title description 22
- 230000014509 gene expression Effects 0.000 claims description 99
- 210000004027 cell Anatomy 0.000 claims description 95
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 77
- 239000013598 vector Substances 0.000 claims description 72
- 238000003776 cleavage reaction Methods 0.000 claims description 65
- 230000007017 scission Effects 0.000 claims description 65
- 125000003729 nucleotide group Chemical group 0.000 claims description 58
- 239000002773 nucleotide Substances 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 56
- 101710113436 GTPase KRas Proteins 0.000 claims description 46
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 43
- 230000009368 gene silencing by RNA Effects 0.000 claims description 43
- 108700042226 ras Genes Proteins 0.000 claims description 40
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 claims description 39
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 claims description 39
- 239000013604 expression vector Substances 0.000 claims description 39
- 230000035772 mutation Effects 0.000 claims description 38
- 230000001419 dependent effect Effects 0.000 claims description 31
- 150000007523 nucleic acids Chemical class 0.000 claims description 30
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 27
- 230000000295 complement effect Effects 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 239000002502 liposome Substances 0.000 claims description 23
- 238000001890 transfection Methods 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 238000012384 transportation and delivery Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 14
- 108020004705 Codon Proteins 0.000 claims description 13
- 238000006467 substitution reaction Methods 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 12
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 239000002105 nanoparticle Substances 0.000 claims description 10
- 230000004565 tumor cell growth Effects 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- 239000002479 lipoplex Substances 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 238000010253 intravenous injection Methods 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 238000002648 combination therapy Methods 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229940034982 antineoplastic agent Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 206010022498 insulinoma Diseases 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 238000003197 gene knockdown Methods 0.000 description 93
- 108090000623 proteins and genes Proteins 0.000 description 78
- 102100030708 GTPase KRas Human genes 0.000 description 63
- 108700028369 Alleles Proteins 0.000 description 46
- 108020004999 messenger RNA Proteins 0.000 description 42
- 102200006538 rs121913530 Human genes 0.000 description 40
- 238000012360 testing method Methods 0.000 description 37
- 230000000694 effects Effects 0.000 description 32
- 108020004459 Small interfering RNA Proteins 0.000 description 31
- 102200006540 rs121913530 Human genes 0.000 description 29
- 229920002477 rna polymer Polymers 0.000 description 28
- 102200006531 rs121913529 Human genes 0.000 description 28
- 241000242739 Renilla Species 0.000 description 27
- 230000008685 targeting Effects 0.000 description 27
- 241000254158 Lampyridae Species 0.000 description 25
- 239000002679 microRNA Substances 0.000 description 23
- 102000053602 DNA Human genes 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 17
- 230000030279 gene silencing Effects 0.000 description 17
- 108700011259 MicroRNAs Proteins 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 15
- 101001120822 Homo sapiens Putative microRNA 17 host gene protein Proteins 0.000 description 14
- 102100026055 Putative microRNA 17 host gene protein Human genes 0.000 description 13
- 238000013461 design Methods 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 108091043187 miR-30a stem-loop Proteins 0.000 description 13
- 230000001404 mediated effect Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 108091070501 miRNA Proteins 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 238000012226 gene silencing method Methods 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 102000004533 Endonucleases Human genes 0.000 description 6
- 108010042407 Endonucleases Proteins 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 108700020796 Oncogene Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 101150105104 Kras gene Proteins 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000003151 transfection method Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 102000008682 Argonaute Proteins Human genes 0.000 description 3
- 108010088141 Argonaute Proteins Proteins 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- 101000574648 Homo sapiens Retinoid-inducible serine carboxypeptidase Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 102000009572 RNA Polymerase II Human genes 0.000 description 3
- 108010009460 RNA Polymerase II Proteins 0.000 description 3
- 102000014450 RNA Polymerase III Human genes 0.000 description 3
- 108010078067 RNA Polymerase III Proteins 0.000 description 3
- 108010052090 Renilla Luciferases Proteins 0.000 description 3
- 102100025483 Retinoid-inducible serine carboxypeptidase Human genes 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 229960005395 cetuximab Drugs 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- -1 promoters Substances 0.000 description 3
- 102000016914 ras Proteins Human genes 0.000 description 3
- 108010014186 ras Proteins Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 3
- 229960003862 vemurafenib Drugs 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 2
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 2
- 238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 2
- 102000034286 G proteins Human genes 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 101000575639 Homo sapiens Ribonucleoside-diphosphate reductase subunit M2 Proteins 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091062156 Mir-19 microRNA precursor family Proteins 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 101150040459 RAS gene Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 102100026006 Ribonucleoside-diphosphate reductase subunit M2 Human genes 0.000 description 2
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 2
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 101150084233 ago2 gene Proteins 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000013043 cell viability test Methods 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000012938 design process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 102000049555 human KRAS Human genes 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000009520 phase I clinical trial Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000009919 sequestration Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- ACEMKCOYIINOHN-UHFFFAOYSA-N 5-methyl-1h-pyrimidine-2,4-dione;pyrimidine Chemical compound C1=CN=CN=C1.CC1=CNC(=O)NC1=O ACEMKCOYIINOHN-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- AXXVSCRPHPIDIW-UHFFFAOYSA-N 7h-purin-6-amine;7h-purine Chemical compound C1=NC=C2NC=NC2=N1.NC1=NC=NC2=C1NC=N2 AXXVSCRPHPIDIW-UHFFFAOYSA-N 0.000 description 1
- 241001143500 Aceraceae Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 101100023118 Danio rerio mfsd6a gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
- 102100036509 Erythropoietin receptor Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
- 102100020948 Growth hormone receptor Human genes 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 1
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102100025608 Major facilitator superfamily domain-containing protein 6 Human genes 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 101150038070 Mfsd6 gene Proteins 0.000 description 1
- 108091028064 Mir-92 microRNA precursor family Proteins 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 101100457843 Schizosaccharomyces pombe (strain 972 / ATCC 24843) tit1 gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010068542 Somatotropin Receptors Proteins 0.000 description 1
- 101150057615 Syn gene Proteins 0.000 description 1
- 241001365914 Taira Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- PGUYAANYCROBRT-UHFFFAOYSA-N dihydroxy-selanyl-selanylidene-lambda5-phosphane Chemical compound OP(O)([SeH])=[Se] PGUYAANYCROBRT-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108091008147 housekeeping proteins Proteins 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 108091023663 let-7 stem-loop Proteins 0.000 description 1
- 108091063478 let-7-1 stem-loop Proteins 0.000 description 1
- 108091049777 let-7-2 stem-loop Proteins 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 108091053735 lin-4 stem-loop Proteins 0.000 description 1
- 108091032363 lin-4-1 stem-loop Proteins 0.000 description 1
- 108091028008 lin-4-2 stem-loop Proteins 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108091091751 miR-17 stem-loop Proteins 0.000 description 1
- 108091069239 miR-17-2 stem-loop Proteins 0.000 description 1
- 108091027698 miR-18-1 stem-loop Proteins 0.000 description 1
- 108091090961 miR-18-2 stem-loop Proteins 0.000 description 1
- 108091050874 miR-19a stem-loop Proteins 0.000 description 1
- 108091086850 miR-19a-1 stem-loop Proteins 0.000 description 1
- 108091088468 miR-19a-2 stem-loop Proteins 0.000 description 1
- 108091087148 miR-20 stem-loop Proteins 0.000 description 1
- 108091066984 miR-20-1 stem-loop Proteins 0.000 description 1
- 108091076199 miR-20-2 stem-loop Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- JRPHGDYSKGJTKZ-UHFFFAOYSA-K selenophosphate Chemical compound [O-]P([O-])([O-])=[Se] JRPHGDYSKGJTKZ-UHFFFAOYSA-K 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
TCGACTGCTGTTGAAGTGAGCGCCGTTGGAGCTGATGGCGTAGTAGTGAAGCCACAGATGTACTACGCCATCAGCTCCAACGTTGCCTACTGCCTCGGAAGCAGCTCACTACATTACTCAGCTGTTGAAGTGAGCGCCGTTGAAGCACGTGGTGTAGTAGTGAAGCCACAGATGTACTACGCCATCAGCTCCAACGTTGCCTACTGCCTCGGAAGCTTAATAAAGGATCTTTTATTTTCATTGGC
TCGACTGCTGTTGAAGTGAGCGCCTTGGAGCTGATGGCGTAGGTAGTGAAGCCACAGATGTACCTACGCCATCAGCTCCAAGTTGCCTACTGCCTCGGAAGCAGCTCACTACATTACTCAGCTGTTGAAGTGAGCGCCTTGGAGCTATAGGTCTAGGTAGTGAAGCCACAGATGTACCTACGCCATCAGCTCCAAGTTGCCTACTGCCTCGGAAGCTTAATAAAGGATCTTTTATTTTCATTGGC
TCGACTGCTGTTGAAGTGAGCGCCTGGAGCTGATGGCGTAGGCTAGTGAAGCCACAGATGTAGCCTACGCCATCAGCTCCAGTTGCCTACTGCCTCGGAAGCAGCTCACTACATTACTCAGCTGTTGAAGTGAGCGCCTGGAGCTGTATGCGTTCGCTAGTGAAGCCACAGATGTAGCCTACGCCATCAGCTCCAGTTGCCTACTGCCTCGGAAGCTTAATAAAGGATCTTTTATTTTCATTGGC
TCGACTGCTGTTGAAGTGAGCGCCGTTGGAGCTGATGGCGTAGTAGTGAAGCCACAGATGTACTATGCCATCAGCTCCAACGTTGCCTACTGCCTCGGAAGCAGCTCACTACATTACTCAGCTGTTGAAGTGAGCGCCGTTGAAGCACGTGGTGTAGTAGTGAAGCCACAGATGTACTATGCCATCAGCTCCAACGTTGCCTACTGCCTCGGAAGCTTAATAAAGGATCTTTTATTTTCATTGGC
TCGACTGCTGTTGAAGTGAGCGCCTTGGAGCTGATGGCGTAGGTAGTGAAGCCACAGATGTACCTATGCCATCAGCTCCAAGTTGCCTACTGCCTCGGAAGCAGCTCACTACATTACTCAGCTGTTGAAGTGAGCGCCTTGGAGCTATAGGTCTAGGTAGTGAAGCCACAGATGTACCTATGCCATCAGCTCCAAGTTGCCTACTGCCTCGGAAGCTTAATAAAGGATCTTTTATTTTCATTGGC
TCGACTGCTGTTGAAGTGAGCGCCTGGAGCTGATGGCGTAGGCTAGTGAAGCCACAGATGTAGCCTATGCCATCAGCTCCAGTTGCCTACTGCCTCGGAAGCAGCTCACTACATTACTCAGCTGTTGAAGTGAGCGCCTGGAGCTGTATGCGTTCGCTAGTGAAGCCACAGATGTAGCCTATGCCATCAGCTCCAGTTGCCTACTGCCTCGGAAGCTTAATAAAGGATCTTTTATTTTCATTGGC
TCGACTGCTGTTGAAGTGAGCGCCGTTGGAGCTCATGGCGTAGTAGTGAAGCCACAGATGTACTACGCCATGAGCTCCAACGTTGCCTACTGCCTCGGAAGCAGCTCACTACATTACTCAGCTGTTGAAGTGAGCGCCGTTGAAGCACGTGGTGTAGTAGTGAAGCCACAGATGTACTACGCCATGAGCTCCAACGTTGCCTACTGCCTCGGAAGCTTAATAAAGGATCTTTTATTTTCATTGGC
TCGACTGCTGTTGAAGTGAGCGCCttggagctCAtggcgtaggTAGTGAAGCCACAGATGTACCTACGCCATGAGCTCCAAGTTGCCTACTGCCTCGGAAGCAGCTCACTACATTACTCAGCTGTTGAAGTGAGCGCCttggagctATAggTCtaggTAGTGAAGCCACAGATGTACCTACGCCATGAGCTCCAAGTTGCCTACTGCCTCGGAAGCTTAATAAAGGATCTTTTATTTTCATTGGC
TCGACTGCTGTTGAAGTGAGCGCCTGGAGCTCATGGCGTAGGCTAGTGAAGCCACAGATGTAGCCTACGCCATGAGCTCCAGTTGCCTACTGCCTCGGAAGCAGCTCACTACATTACTCAGCTGTTGAAGTGAGCGCCTGGAGCTGTATGCGTTCGCTAGTGAAGCCACAGATGTAGCCTACGCCATGAGCTCCAGTTGCCTACTGCCTCGGAAGCTTAATAAAGGATCTTTTATTTTCATTGGC
TCGACTGCTGTTGAAGTGAGCGCCGTGGTAGTTGGAGCTGTTGTAGTGAAGCCACAGATGTACAACAGCTCCAACTACCACGTTGCCTACTGCCTCGGAAGCAGCTCACTACATTACTCAGCTGTTGAAGTGAGCGCCGTGGTAGTCTTAGCTATTGTAGTGAAGCCACAGATGTACAACAGCTCCAACTACCACGTTGCCTACTGCCTCGGAAGCTTAATAAAGGATCTTTTATTTTCATTGGC
TCGACTGCTGTTGAAGTGAGCGCCTGGTAGTTGGAGCTGTTGGTAGTGAAGCCACAGATGTACCAACAGCTCCAACTACCAGTTGCCTACTGCCTCGGAAGCAGCTCACTACATTACTCAGCTGTTGAAGTGAGCGCCTGGTAGTTACTGCTATTGGTAGTGAAGCCACAGATGTACCAACAGCTCCAACTACCAGTTGCCTACTGCCTCGGAAGCTTAATAAAGGATCTTTTATTTTCATTGGC
TCGACTGCTGTTGAAGTGAGCGCCTGTGGTAGTTGGAGCTCGTTAGTGAAGCCACAGATGTAACGAGCTCCAACTACCACAGTTGCCTACTGCCTCGGAAGCAGCTCACTACATTACTCAGCTGTTGAAGTGAGCGCCTGTGGTAGACTGAGCTAGTTAGTGAAGCCACAGATGTAACGAGCTCCAACTACCACAGTTGCCTACTGCCTCGGAAGCTTAATAAAGGATCTTTTATTTTCATTGGC
TCGACTGCTGTTGAAGTGAGCGCCGTGGTAGTTGGAGCTCGTGTAGTGAAGCCACAGATGTACACGAGCTCCAACTACCACGTTGCCTACTGCCTCGGAAGCAGCTCACTACATTACTCAGCTGTTGAAGTGAGCGCCGTGGTAGTACTAGCTAGTGTAGTGAAGCCACAGATGTACACGAGCTCCAACTACCACGTTGCCTACTGCCTCGGAAGCTTAATAAAGGATCTTTTATTTTCATTGGC
TCGACTGCTGTTGAAGTGAGCGCCTGTGGTAGTTGGAGCTTGTTAGTGAAGCCACAGATGTAACAAGCTCCAACTACCACAGTTGCCTACTGCCTCGGAAGCAGCTCACTACATTACTCAGCTGTTGAAGTGAGCGCCTGTGGTAGACTGAGCTAGTTAGTGAAGCCACAGATGTAACAAGCTCCAACTACCACAGTTGCCTACTGCCTCGGAAGCTTAATAAAGGATCTTTTATTTTCATTGGC
TCGACTGCTGTTGAAGTGAGCGCCGTGGTAGTTGGAGCTTGTGTAGTGAAGCCACAGATGTACACAAGCTCCAACTACCACGTTGCCTACTGCCTCGGAAGCAGCTCACTACATTACTCAGCTGTTGAAGTGAGCGCCGTGGTAGTCTTAGCTTATGTAGTGAAGCCACAGATGTACACAAGCTCCAACTACCACGTTGCCTACTGCCTCGGAAGCTTAATAAAGGATCTTTTATTTTCATTGGC
(配列番号23)
(配列番号25)
配列番号57
(配列番号53)
(配列番号54)
(配列番号55)
(配列番号56)
1.Ohnishi Y, Tokunaga K, Kaneko K, Hohjoh H. Assessment of allele-specific gene silencing by RNA interference with mutant and wild-type reporter alleles. J RNAi Gene Silencing. 2006 Feb 28;2(1):154-60
2.Huang H, Qiao R, Zhao D, Zhang T, Li Y, Yi F, Lai F, Hong J, Ding X, Yang Z, Zhang L, Du Q, Liang Z. Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs. Nucleic Acids Res. 2009 Dec;37(22):7560-9
3.Schwarz DS, Ding H, Kennington L, Moore JT, Schelter J, Burchard J, Linsley PS, Aronin N, Xu Z, Zamore PD. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet. 2006 Sep 8;2(9):e140
4.Geng CM, Ding HL. Design of functional small interfering RNAs targeting amyotrophic lateral sclerosis-associated mutant alleles. Chin Med J (Engl). 2011 Jan;124(1):106-10
5.Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2002 Sep;2(3):243-7
6.Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res. 2005 Jul;3(7):413-23
7.Zhang Z, Jiang G, Yang F, Wang J. Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells. Cancer Biol Ther. 2006 Nov;5(11):1481-6
8.Smakman N, Veenendaal LM, van Diest P, Bos R, Offringa R, Borel Rinkes IH, Kranenburg O. Dual effect of Kras(D12) knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy. Oncogene. 2005 Dec 15;24(56):8338-42
9.Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res. 2006 Oct 1;66(19):9736-43
10.Sierant M, Paduszynska A, Kazmierczak-Baranska J, Nacmias B, Sorbi S, Bagnoli S, Sochacka E, Nawrot B. Specific Silencing of L392V PSEN1 Mutant Allele by RNA Interference. Int J Alzheimers Dis. 2011 Apr 7;2011:809218
11.de Ynigo-Mojado L, Martin-Ruiz I, Sutherland JD. Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi. PLoS One. 2011;6(6):e21352
12.Takahashi M, Watanabe S, Murata M, Furuya H, Kanazawa I, Wada K, Hohjoh H. Tailor-made RNAi knockdown against triplet repeat disease-causing alleles. Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21731-6
13.Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, DiFiglia M, Landwehrmeyer B, Vonsattel JP, Zamore PD, Aronin N. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol. 2009 May 12;19(9):774-8
14.Rao DD, Maples PB, Senzer N, Kumar P, Wang Z, Pappen BO, Yu Y, Haddock C, Jay C, Phadke AP, Chen S, Kuhn J, Dylewski D, Scott S, Monsma D, Webb C, Tong A, Shanahan D, Nemunaitis J. Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference. Cancer Gene Ther. 2010 Nov;17(11):780-91
15.Rao DD, Senzer N, Wang Z, Kumar P, Jay CM, Nemunaitis J. Bi-functional Short Hairpin RNA (bi-shRNA): Design and Pathway to Clinical Application. Methods Mol Biol. 2012
Claims (16)
- KRASのコドン12にアミノ酸置換変異を生じる変異K−ras遺伝子産物の発現を選択的に減少させる二機能性shRNAであって、前記二機能性shRNAのガイド鎖が、前記変異K−ras遺伝子の標的部位配列に完全に相補的であり、
KRASのコドン12にアミノ酸置換変異を生じる変異ヌクレオチドが、前記二機能性shRNA内のシード配列の2、3又は4位に位置し、
前記二機能性shRNAのパッセンジャー鎖の1つが、前記二機能性shRNAのガイド鎖と比較して1又は2以上のミスマッチを含み、
前記二機能性shRNA分子が、前記変異K−ras遺伝子産物の発現レベルを選択的に減少させるための切断依存性及び切断非依存性RNA誘導サイレンシング複合体を活性化する、
前記二機能性shRNA。 - 配列番号2、3、17〜22、又は53〜56により定義される少なくとも1つのヌクレオチド配列を含む、請求項1に記載の二機能性shRNA。
- ヒトK−ras遺伝子cDNA配列内の少なくとも1つの標的部位配列が、配列番号32、33又は47〜52により定義される少なくとも1つのヌクレオチド配列を含む、請求項1に記載の二機能性shRNA。
- プロモーターと、
RNA干渉によって、KRASのコドン12にアミノ酸置換変異を生じる少なくとも1つの変異K−ras遺伝子産物の発現を選択的に阻害する1又は2以上のshRNAをコードする、前記プロモーターに作動可能に連結されている核酸インサートと
を含む発現ベクターであって、
前記1又は2以上のshRNAが、二機能性shRNA分子を含み、
前記二機能性shRNAのガイド鎖が、前記変異K−ras遺伝子の標的部位配列に完全に相補的であり、
KRASのコドン12にアミノ酸置換変異を生じる変異ヌクレオチドが、前記二機能性shRNA内のシード配列の2、3又は4位に位置し、
前記二機能性shRNAのパッセンジャー鎖の1つが、前記二機能性shRNAのガイド鎖と比較して1又は2以上のミスマッチを含み、
前記二機能性shRNAが、前記少なくとも1つの変異K−ras遺伝子産物の発現を選択的に減少させるために切断依存性及び切断非依存性RNA誘導サイレンシング複合体を活性化する、
前記発現ベクター。 - shRNAのための二機能性配列配置が、K−ras−TA−15ヌクレオチドループ−19ヌクレオチド標的相補的配列−3’ステムアーム−スペーサー−5’ステムアーム−19ヌクレオチド標的バリアント−TA−15ヌクレオチドループ−19ヌクレオチド標的相補的配列−3’ステムアームである、5’ステムアーム−19ヌクレオチド標的を含む、請求項4に記載の発現ベクター。
- 核酸インサートが、配列番号2、3、17〜22、又は53〜56から選択される少なくとも1つのヌクレオチド配列を含むか、標的部位配列が、配列番号32、33、又は47〜52から選択される少なくとも1つのヌクレオチド配列を含む、請求項4又は5に記載の発現ベクター。
- 1、2、3、4、5、6、7、8、9、又は10コピーの二機能性shRNAインサートを含む、請求項4〜6のいずれかに記載の発現ベクター。
- 治療薬担体と、
請求項4〜7のいずれかに記載の発現ベクターと
を含む治療送達システム。 - 治療薬担体が、緻密化されたDNAナノ粒子であるか、或いは1若しくは2以上のポリカチオンで緻密化されたDNAナノ粒子である、請求項8に記載の送達システム。
- 1又は2以上の変異K−ras遺伝子産物を発現している標的組織に1又は2以上のshRNAを送達するための方法に使用するための、請求項8又は9に記載の治療送達システムであって、
前記方法が、
請求項4〜7のいずれかに記載の発現ベクターを調製するステップと、
前記発現ベクターを、リポソームを含む治療薬担体と組み合わせるステップと、
治療的有効量の前記発現ベクターと治療薬担体複合体を、それを必要とする患者に投与するステップと
を含む、
前記治療送達システム。 - 1又は2以上の標的細胞において、KRASのコドン12にアミノ酸置換変異を生じる変異K−ras遺伝子産物の発現をインビトロで阻害する方法であって、
選択された1又は2以上の標的細胞にRNA干渉を通じて前記1又は2以上の標的細胞において、前記変異K−ras遺伝子産物の発現を阻害することができる1又は2以上の低分子ヘアピン型RNA(shRNA)を発現するベクターをトランスフェクトするステップを含み、
前記1又は2以上のshRNAが、二機能性shRNA分子を含み、
前記二機能性shRNAのガイド鎖が、前記変異K−ras遺伝子の標的部位配列に完全に相補的であり、
KRASのコドン12にアミノ酸置換変異を生じる変異ヌクレオチドが、前記二機能性shRNA内のシード配列の2、3又は4位に位置し、
前記二機能性shRNAのパッセンジャー鎖の1つが、前記二機能性shRNAのガイド鎖と比較して1又は2以上のミスマッチを含み、
前記1又は2以上の二機能性shRNAが、前記変異K−ras遺伝子産物の発現を選択的に減少させるための切断依存性及び切断非依存性RNA誘導サイレンシング複合体を活性化する、
前記方法。 - ヒト対象において腫瘍細胞増殖を抑制する方法に使用するための、請求項4〜7のいずれかに記載の発現ベクターであって、
前記方法が、
腫瘍細胞増殖の抑制を必要とするヒト対象を特定するステップと、
治療薬担体複合体中の前記発現ベクターを、前記腫瘍細胞増殖を抑制するのに十分な量で前記ヒト対象に投与するステップとを含む、
前記発現ベクター。 - i)投与が、腫瘍内注射、皮下注射、静脈内注射、腹腔内注射、筋肉内注射、及びDNA:リポプレックスを用いた注射からなる群から選択されるか、
ii)腫瘍細胞が変異K−ras遺伝子産物を発現しているか、
iii)腫瘍が、ヒト膵管腺癌、肺がん、結腸がん、黒色腫、インスリノーマ、中皮腫、卵巣がん、及び膵臓がんからなる群から選択されるか、
iv)二機能性shRNAが配列番号2、3、17〜22、又は53〜56から選択される少なくとも1つのヌクレオチド配列を含むか、及び/或いは
v)方法が、第2の抗新生物薬との併用療法をさらに含む、
請求項12に記載の使用するための発現ベクター。 - KRASのコドン12にアミノ酸置換変異を生じる変異K−ras遺伝子産物の発現を選択的に減少させる、1、2、3、4、5、6、7、8、9、又は10の二機能性shRNAをコードする核酸インサートを含む発現ベクターであって、
前記二機能性shRNA分子が、前記変異K−ras遺伝子の標的部位配列に完全に相補的であるガイド鎖shRNAを含み、
KRASのコドン12にアミノ酸置換変異を生じる変異ヌクレオチドが、前記二機能性shRNA内のシード配列の2、3又は4位に位置し、
前記二機能性shRNAのパッセンジャー鎖の1つが、前記二機能性shRNAのガイド鎖と比較して1又は2以上のミスマッチを含み、
前記1又は2以上の二機能性shRNAが、前記変異K−ras遺伝子産物の発現を選択的に減少させるための切断依存性及び切断非依存性RNA誘導サイレンシング複合体を活性化する、
前記発現ベクター。 - KRASのコドン12にアミノ酸置換変異を生じる変異K−ras遺伝子産物の発現を選択的に減少させる、1、2、3、4、5、6、7、8、9、又は10の二機能性shRNAインサートを包含する発現ユニットを含む細胞であって、
前記二機能性shRNA分子の少なくとも1つの標的部位配列が、前記変異K−ras遺伝子内に位置しており、
前記二機能性shRNA分子が、前記変異K−ras遺伝子の標的部位配列に完全に相補的であるガイド鎖を含み、
KRASのコドン12にアミノ酸置換変異を生じる変異ヌクレオチドが、前記二機能性shRNA内のシード配列の2、3又は4位に位置し、
前記二機能性shRNAのパッセンジャー鎖の1つが、前記二機能性shRNAのガイド鎖と比較して1又は2以上のミスマッチを含み、
前記二機能性shRNAが、前記変異K−ras遺伝子産物の発現を選択的に減少させるための切断依存性及び切断非依存性RNA誘導サイレンシング複合体を活性化する、
前記細胞。 - 二機能性shRNAが配列番号2、3、17〜22、又は53〜56から選択される少なくとも1つのヌクレオチド配列を含むか、或いは、野生型K−rasの発現を増加させる、請求項15に記載の細胞。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261644875P | 2012-05-09 | 2012-05-09 | |
US61/644,875 | 2012-05-09 | ||
US13/890,957 US9353373B2 (en) | 2012-05-09 | 2013-05-09 | Bi-functional short-hairpin RNA (bi-shRNA) specific for single-nucleotide KRAS mutations |
US13/890,957 | 2013-05-09 | ||
PCT/US2013/040407 WO2013170071A1 (en) | 2012-05-09 | 2013-05-09 | Bi-functional short-hairpin rna (bi-shrna) specific for single-nucleotide kras mutations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017131718A Division JP2017221198A (ja) | 2012-05-09 | 2017-07-05 | 一塩基KRAS変異に特異的な二機能性低分子ヘアピン型RNA(BI−SHRNA,Bi−functional Short−Hairpin RNA) |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015521040A JP2015521040A (ja) | 2015-07-27 |
JP6283661B2 true JP6283661B2 (ja) | 2018-02-21 |
Family
ID=49548788
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015511715A Active JP6283661B2 (ja) | 2012-05-09 | 2013-05-09 | 一塩基KRAS変異に特異的な二機能性低分子ヘアピン型RNA(BI−SHRNA,Bi−functionalShort−HairpinRNA) |
JP2017131718A Pending JP2017221198A (ja) | 2012-05-09 | 2017-07-05 | 一塩基KRAS変異に特異的な二機能性低分子ヘアピン型RNA(BI−SHRNA,Bi−functional Short−Hairpin RNA) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017131718A Pending JP2017221198A (ja) | 2012-05-09 | 2017-07-05 | 一塩基KRAS変異に特異的な二機能性低分子ヘアピン型RNA(BI−SHRNA,Bi−functional Short−Hairpin RNA) |
Country Status (13)
Country | Link |
---|---|
US (2) | US9353373B2 (ja) |
EP (1) | EP2847333A4 (ja) |
JP (2) | JP6283661B2 (ja) |
KR (1) | KR20150006477A (ja) |
CN (1) | CN104685055A (ja) |
AR (1) | AR091004A1 (ja) |
AU (1) | AU2013259387B2 (ja) |
CA (1) | CA2872930A1 (ja) |
IL (1) | IL235486A0 (ja) |
MX (1) | MX2014013475A (ja) |
SG (1) | SG11201407239SA (ja) |
TW (1) | TW201402813A (ja) |
WO (1) | WO2013170071A1 (ja) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8252526B2 (en) * | 2006-11-09 | 2012-08-28 | Gradalis, Inc. | ShRNA molecules and methods of use thereof |
KR101589951B1 (ko) | 2009-12-23 | 2016-01-29 | 그래댈리스, 인코포레이티드 | 푸린―녹다운 및 gm―csf―증강된 (fang) 암 백신 |
JP6283661B2 (ja) * | 2012-05-09 | 2018-02-21 | ストライク バイオ インク.Strike Bio,Inc. | 一塩基KRAS変異に特異的な二機能性低分子ヘアピン型RNA(BI−SHRNA,Bi−functionalShort−HairpinRNA) |
US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
US11885816B2 (en) * | 2013-11-26 | 2024-01-30 | University Of North Texas Health Science Center At Forth Worth | Personalized medicine approach for treating cognitive loss |
LU92353A1 (en) * | 2014-01-14 | 2015-07-15 | Univ Muenster Wilhelms | Antibody-mediated delivery of RNAI |
CN106661576A (zh) * | 2014-04-25 | 2017-05-10 | 斯特里克生物公司 | 用于癌症治疗的多靶向RNAi |
WO2015164818A1 (en) * | 2014-04-25 | 2015-10-29 | Strike Bio, Inc. | Multiple targeted rnai for the treatment of cancers |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
ES2826443T3 (es) | 2014-09-25 | 2021-05-18 | Araxes Pharma Llc | Inhibidores de proteínas mutantes KRAS G12C |
WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
MX2017012979A (es) | 2015-04-10 | 2017-11-28 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y metodos de uso de los mismos. |
JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Krasの縮合三環系インヒビターおよびその使用の方法 |
KR20180017119A (ko) * | 2015-06-10 | 2018-02-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 질환의 치료를 위한 엑소좀의 용도 |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356351A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
EP3445392A1 (en) * | 2016-04-22 | 2019-02-27 | CureVac AG | Rna encoding a tumor antigen |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
JP2019534260A (ja) | 2016-10-07 | 2019-11-28 | アラクセス ファーマ エルエルシー | Rasの阻害剤としての複素環式化合物およびその使用方法 |
WO2018098352A2 (en) * | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
WO2018140600A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
CN110430894A (zh) * | 2017-02-01 | 2019-11-08 | 莫得纳特斯公司 | 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物 |
WO2018218071A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
EP3630747A1 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Quinazoline derivatives as modulators of mutant kras, hras or nras |
JP2020521742A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | Krasの共有結合性阻害剤 |
WO2018225873A1 (ja) * | 2017-06-09 | 2018-12-13 | 協和発酵キリン株式会社 | 核酸含有ナノ粒子 |
KR20220124817A (ko) | 2017-08-07 | 2022-09-14 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 안전한 세포 치료제를 생성하기 위한 플랫폼 |
JP7419268B2 (ja) * | 2018-03-02 | 2024-01-22 | エリシオ セラピューティクス, インク. | 変異kras配列及び脂質を含む化合物並びにその使用 |
WO2019204624A1 (en) * | 2018-04-19 | 2019-10-24 | Board Of Regents, The University Of Texas System | Therapeutic modulation of tumor suppressors using exosomes |
WO2019226612A1 (en) * | 2018-05-21 | 2019-11-28 | The United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for treating rsv-infections |
WO2021030781A1 (en) * | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with antisense oligonucleotides targeting kras |
CN110835644B (zh) * | 2019-12-16 | 2021-08-17 | 广州市宝创生物技术有限公司 | K-ras基因突变位点检测试剂盒 |
CN112980840A (zh) * | 2019-12-17 | 2021-06-18 | 南京大学 | 用于癌症治疗的多靶向siRNA |
KR102574252B1 (ko) * | 2020-12-15 | 2023-09-07 | 주식회사 시선테라퓨틱스 | 펩티드 핵산 복합체를 유효성분으로 함유하는 췌장암 예방 또는 치료용 조성물 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050288242A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA) |
WO2005044981A2 (en) * | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
CN101563104A (zh) * | 2006-02-01 | 2009-10-21 | 约翰霍普金斯大学 | 用于肿瘤或传染性疾病免疫预防或免疫治疗的多肽-核酸结合物 |
PT2712618T (pt) * | 2006-06-23 | 2017-01-26 | Engeneic Molecular Delivery Pty Ltd | Entrega localizada de fármacos, ácidos nucleicos terapêuticos e ácidos nucleicos funcionais a células de mamíferos por meio de células bacterianas exterminadas intactas |
US8252526B2 (en) * | 2006-11-09 | 2012-08-28 | Gradalis, Inc. | ShRNA molecules and methods of use thereof |
WO2008137066A1 (en) * | 2007-05-02 | 2008-11-13 | The Board Of Regents Of The University Of Oklahoma | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
JP2010538678A (ja) * | 2007-09-18 | 2010-12-16 | イントラドイグム コーポレーション | K−rassiRNA含有組成物及びそれらの使用法 |
WO2011053660A2 (en) | 2009-10-30 | 2011-05-05 | Gradalis, Inc. | Novel therapeutic rna interference technology targeted to the pdx-1 oncogene in pdx-1 expressing neuroendocrine tumors |
JP6283661B2 (ja) * | 2012-05-09 | 2018-02-21 | ストライク バイオ インク.Strike Bio,Inc. | 一塩基KRAS変異に特異的な二機能性低分子ヘアピン型RNA(BI−SHRNA,Bi−functionalShort−HairpinRNA) |
-
2013
- 2013-05-09 JP JP2015511715A patent/JP6283661B2/ja active Active
- 2013-05-09 CA CA2872930A patent/CA2872930A1/en not_active Abandoned
- 2013-05-09 EP EP13788485.4A patent/EP2847333A4/en active Pending
- 2013-05-09 CN CN201380036406.9A patent/CN104685055A/zh active Pending
- 2013-05-09 AU AU2013259387A patent/AU2013259387B2/en not_active Ceased
- 2013-05-09 AR ARP130101611A patent/AR091004A1/es unknown
- 2013-05-09 SG SG11201407239SA patent/SG11201407239SA/en unknown
- 2013-05-09 KR KR1020147034469A patent/KR20150006477A/ko not_active Application Discontinuation
- 2013-05-09 WO PCT/US2013/040407 patent/WO2013170071A1/en active Application Filing
- 2013-05-09 US US13/890,957 patent/US9353373B2/en active Active
- 2013-05-09 MX MX2014013475A patent/MX2014013475A/es unknown
- 2013-05-09 TW TW102116636A patent/TW201402813A/zh unknown
-
2014
- 2014-11-03 IL IL235486A patent/IL235486A0/en unknown
-
2016
- 2016-04-28 US US15/141,280 patent/US20160333351A1/en not_active Abandoned
-
2017
- 2017-07-05 JP JP2017131718A patent/JP2017221198A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2013259387A1 (en) | 2014-11-20 |
US20130302407A1 (en) | 2013-11-14 |
MX2014013475A (es) | 2015-05-15 |
JP2015521040A (ja) | 2015-07-27 |
US20160333351A1 (en) | 2016-11-17 |
CA2872930A1 (en) | 2013-11-14 |
AR091004A1 (es) | 2014-12-30 |
JP2017221198A (ja) | 2017-12-21 |
US9353373B2 (en) | 2016-05-31 |
IL235486A0 (en) | 2014-12-31 |
TW201402813A (zh) | 2014-01-16 |
WO2013170071A1 (en) | 2013-11-14 |
CN104685055A (zh) | 2015-06-03 |
EP2847333A4 (en) | 2015-12-16 |
EP2847333A1 (en) | 2015-03-18 |
SG11201407239SA (en) | 2014-12-30 |
KR20150006477A (ko) | 2015-01-16 |
AU2013259387B2 (en) | 2016-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6283661B2 (ja) | 一塩基KRAS変異に特異的な二機能性低分子ヘアピン型RNA(BI−SHRNA,Bi−functionalShort−HairpinRNA) | |
US9683237B2 (en) | Multiple targeted RNAI for the treatment of cancers | |
Chi et al. | Safety of antisense oligonucleotide and siRNA-based therapeutics | |
EP2316491B1 (en) | Cell proliferation inhibitor | |
US8758998B2 (en) | Construction of bifunctional short hairpin RNA | |
JP6007103B2 (ja) | Pdx−1発現神経内分泌腫瘍中のpdx−1オンコジーンを標的とする新規な治療的rna干渉技術 | |
Valdmanis et al. | RNA interference–induced hepatotoxicity results from loss of the first synthesized isoform of microRNA-122 in mice | |
JP2011507554A (ja) | 遺伝子発現を増加させるための方法および組成物 | |
Pai et al. | Prospects of miRNA-based therapy for pancreatic cancer | |
EP3134528A1 (en) | Multiple targeted rnai for the treatment of cancers | |
JP2017511694A (ja) | マイクロrna阻害剤を使用するための組成物および方法 | |
Atri et al. | MicroRNAs in diagnosis and therapeutics | |
AU2017276806A1 (en) | Methods of treating neuroblastoma and reagents therefor | |
WO2017005773A1 (en) | Use of catenin- beta 1-targeting micrornas for treating liver cancer | |
WO2018152524A1 (en) | Toxic rnai active seed sequences for killing cancer cells | |
JP7179744B2 (ja) | アプタマー変調RNase P切断による遺伝子発現の調節 | |
US9512425B2 (en) | Inhibiting migration of cancer cells | |
US20130259926A1 (en) | BI-FUNCTIONAL shRNA TARGETING MESOTHELIN AND USES THEREOF | |
JP2022541212A (ja) | 治療的使用のための、ヒト遺伝子JAK1又はJAK3の発現を標的とするSiRNA配列 | |
Zhu | RNA pull-down-confocal nanoscanning (RP-CONA), a novel method for studying RNA/protein interactions in cell extracts that detected potential drugs for Parkinson’s disease targeting RNA/HuR complexes | |
Li | The Role of Circular RNAs in Cardiac Remodeling | |
Jian et al. | RNA therapy: Are we using the right molecules? | |
WO2018144587A1 (en) | Steap2 inhibitors for the treatment of liver cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150521 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150521 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20150914 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160426 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160720 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161020 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170306 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180129 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6283661 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |